scholarly journals Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans.

1995 ◽  
Vol 63 (10) ◽  
pp. 4105-4114 ◽  
Author(s):  
Y A Skeiky ◽  
D R Benson ◽  
J A Guderian ◽  
J A Whittle ◽  
O Bacelar ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Proteins ◽  
Immune Responses ◽  
Leishmania Species ◽  
Shock Proteins

scholarly journals Myeloma cell line–derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

Blood ◽  
2009 ◽  
Vol 114 (18) ◽  
pp. 3880-3889 ◽  
Author(s):  
Jianfei Qian ◽  
Sungyoul Hong ◽  
Siqing Wang ◽  
Liang Zhang ◽  
Luhong Sun ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Proteins ◽  
Immune Responses ◽  
Cell Line ◽  
Cell Lines ◽  
Tumor Antigens ◽  
Myeloma Cell ◽  
Myeloma Cell Line ◽  
Custom Made ◽  
Shock Proteins

Abstract Tumor cell–derived heat shock proteins are used as vaccines for immunotherapy of cancer patients. However, current approaches require the generation of custom-made products and are clinically ineffective. To improve the applicability of heat shock protein–based immunotherapy in cancers and to enhance clinical efficacy, we explored combinational treatments in a myeloma setting using pooled heterogeneous or allogeneic myeloma cell line–derived glycoprotein 96 (gp96) as universal vaccines, and clearly demonstrated that pooled but not single gp96 from heterogeneous or allogeneic myeloma cell lines was as effective as autologous gp96 in protecting mice from tumor challenge and rechallenge and in treating established myeloma. We showed that interferon γ and CD4+ and CD8+ T cells were required for gp96-induced antimyeloma responses and that pooled gp96 induced broader immune responses that protected mice from developing different myeloma. Furthermore, pooled gp96 plus CpG in combination with anti-B7H1 or anti–interleukin-10 monoclonal antibodies were effective in treating mice with large tumor burdens. Thus, this study strongly suggests that pooled gp96 vaccines from myeloma cell lines can replace gp96 vaccines from autologous tumors for immunotherapy and induce immune responses against broader tumor antigens that may protect against tumor recurrence and development of unrelated tumors in vaccinated myeloma patients.

scholarly journals CD91-Dependent Modulation of Immune Responses by Heat Shock Proteins: A Role in Autoimmunity

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Robert J. Binder ◽  
Yu Jerry Zhou ◽  
Michelle N. Messmer ◽  
Sudesh Pawaria
Keyword(s):  
Infectious Disease ◽  
Heat Shock ◽  
Heat Shock Proteins ◽  
Immune Responses ◽  
Autoimmune Diseases ◽  
Clinical Application ◽  
Clinical Setting ◽  
Cellular Level ◽  
Immunotherapy Of Cancer ◽  
Shock Proteins

Heat shock proteins (HSPs) have been known for decades for their ability to protect cells under stressful conditions. In the 1980s a new role was ascribed for several HSPs given their ability to elicit specific immune responses in the setting of cancer and infectious disease. These immune responses have primarily been harnessed for the immunotherapy of cancer in the clinical setting. However, because of the ability of HSPs to prime diverse immune responses, they have also been used for modulation of immune responses during autoimmunity. The apparent dichotomy of immune responses elicited by HSPs is discussed here on a molecular and cellular level. The potential clinical application of HSP-mediated immune responses for therapy of autoimmune diseases is reviewed.

Sign in / Sign up

Export Citation Format

Share Document